Percheron Therapeutics (ASX:PER) has one of the most promising oncology assets in HMBD-002. HMBD-002 is an immune-oncology therapy (meaning it utilises a patient’s immune system) that inhibits a pathway called VISTA that plays a key role in suppressing T-cell responses to cancer treatments. Following positive Phase 1 data, Percheron is taking HMBD-002 into Phase 2 […]